Reducing the Immunogenicity of Protein Therapeutics

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|10|2|131-139

ISSN： 1389-4501

Source： Current Drug Targets, Vol.10, Iss.2, 2009-02, pp. : 131-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Minimizing the immunogenicity of protein therapeutics

By Chirino A.J.   Ary M.L.   Marshall S.A.  

Drug Discovery Today, Vol. 9, Iss. 2, 2004-01 ,pp. : 82-90

Elsevier

Access to resources Recommend Favorite

Immunogenicity of therapeutics: a matter of efficacy and safety

By Nechansky Andreas   Kircheis Ralf  

Expert Opinion on Drug Discovery, Vol. 5, Iss. 11, 2010-11 ,pp. : 1067-1079

Informa Healthcare

Access to resources Recommend Favorite

Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk

By Janero David R   Lindsley Loren   Vemuri Venkata Kiran   Makriyannis Alexandros  

Expert Opinion on Drug Discovery, Vol. 6, Iss. 10, 2011-10 ,pp. : 995-1025

Informa Healthcare

Access to resources Recommend Favorite

Rational engineering of protein therapeutics

By  

Inpharma, Vol. 1, Iss. 1383-1384, 2003-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Inhalation Delivery of Protein Therapeutics

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 12, Iss. 2, 2013-04 ,pp. : 81-87

Bentham Science Publishers

Access to resources Recommend Favorite